ContextVision AB
OSE:CONTX
ContextVision AB
ContextVision AB operates as a medical technology software company that specializes in image analysis and artificial intelligence. The company is headquartered in Stockholm, Stockholm and currently employs 53 full-time employees. The firm's products are tailored primarily for medical imaging equipment manufacturers. Its product portfolio is structured into six groups, namely Mammography, comprising such products, as GOPView MAMMO, MAMMO PLUSViev and C-CAD; Ultrasound, comprising the US PlusView family of products, GOPView USXI and GOPiCE US products; Magnetic Resonance Imagining (MRI), comprising the GOPView MRI2 product; Computer tomography (CT), comprising the GOPView CT software; Digital X-Ray, comprising such products, as GOPView XR2 and GOPView XR2-DI, among others, and Interventional Radiology/Fluoroscopy, comprising the GOPView IRV Plus and GOPView IRV Ultra products. As of December 31, 2011, the Company had one wholly owned subsidiary, ContextVision Inc, based in the United States.
ContextVision AB operates as a medical technology software company that specializes in image analysis and artificial intelligence. The company is headquartered in Stockholm, Stockholm and currently employs 53 full-time employees. The firm's products are tailored primarily for medical imaging equipment manufacturers. Its product portfolio is structured into six groups, namely Mammography, comprising such products, as GOPView MAMMO, MAMMO PLUSViev and C-CAD; Ultrasound, comprising the US PlusView family of products, GOPView USXI and GOPiCE US products; Magnetic Resonance Imagining (MRI), comprising the GOPView MRI2 product; Computer tomography (CT), comprising the GOPView CT software; Digital X-Ray, comprising such products, as GOPView XR2 and GOPView XR2-DI, among others, and Interventional Radiology/Fluoroscopy, comprising the GOPView IRV Plus and GOPView IRV Ultra products. As of December 31, 2011, the Company had one wholly owned subsidiary, ContextVision Inc, based in the United States.
Revenue: Fourth quarter revenue was SEK 31.7 million, down 7.3% year-on-year due to currency headwinds.
Profitability: Adjusted EBITDA margin for Q4 was 24.9%, showing some recovery but down from 33.4% last year.
Market Stabilization: Management noted early signs of stabilization in both the broader market and company performance in Q4.
Transformation Progress: The company hit a major milestone by enrolling its first patient in a clinical study for new data quality products.
Product Launches: A new line of clinically focused products was launched at RSNA 2025.
Cash Position: Ended the year with SEK 69.8 million in cash, providing a solid financial base despite negative cash flow for the year.
